Revenue: As of FY2026 Q2, the actual value is USD 2.96 B, beating the estimate of USD 2.796 B.

EPS: As of FY2026 Q2, the actual value is USD 0.24.

EBIT: As of FY2026 Q2, the actual value is USD 222 M.

Dividend Information

Baxter International Inc. declared a quarterly cash dividend of $0.01 per share of common stock, payable on October 1, 2026, to stockholders of record as of August 28, 2026.

Second Quarter 2026 Financial Highlights

Company-wide Performance (Continuing Operations)

• Worldwide Sales: Baxter International Inc. reported worldwide sales of $2.96 billion, marking an increase of 5% on both a reported and organic basis compared to the prior year.
• U.S. Sales: U.S. sales were $1.6 billion, up 4% on both a reported and organic basis.
• International Sales: International sales reached $1.4 billion, increasing 7% on a reported basis and 5% on an organic basis.
• Net Income (U.S. GAAP): Net income totaled $135 million.
• Adjusted Net Income Attributable to Baxter Stockholders: Adjusted net income attributable to Baxter stockholders was $281 million, a 2% increase from $276 million in the prior year.
• Gross Margin: The gross margin was $1,032 million, up 4% from $991 million in the prior year, representing 34.9% of net sales, a decrease of 0.4 percentage points.
• Operating Income: Operating income was $217 million, a 14% increase from $191 million in the prior year, representing 7.3% of net sales, an increase of 0.5 percentage points.
• Adjusted Operating Income: Adjusted operating income was $421 million, reflecting a -0% change from $423 million in the prior year.
• Operating Costs:
  • Selling, General and Administrative Expenses: $735 million, up 2% from $718 million in the prior year, representing 24.8% of net sales.
  • Research and Development Expenses: $129 million, down -4% from $134 million in the prior year, representing 4.4% of net sales.
• Free Cash Flow: Free cash flow was $181 million for the second quarter.

Segment Revenue (Second Quarter 2026)

• Medical Products & Therapies: Total sales were $2.1 billion, increasing 7% on a reported basis and 5% on an organic basis.
  • Infusion Therapies & Platforms: $1,745 million, up 6% (reported) and 4% (organic).
  • Advanced Surgery: $331 million, up 12% (reported and organic).
• Healthcare Systems & Technologies: Total sales were $801 million, increasing 4% on both a reported and organic basis.
  • Care & Connectivity Solutions: $502 million, up 6% (reported) and 5% (organic).
  • Front Line Care: $299 million, up 2% (reported and organic).
• Other: Sales were $83 million, a -15% reported change and 0% organic change.

First Half 2026 Financial Highlights

Company-wide Performance (Continuing Operations)

• Net Sales: Total net sales for the six months ended June 30, 2026, were $5,661 million, a 4% increase from $5,435 million in the prior year.
• Net Income (U.S. GAAP): Net income for the six months was $111 million, a -49% change from $217 million in the prior year.
• Adjusted Net Income Attributable to Baxter Stockholders: Adjusted net income attributable to Baxter stockholders was $471 million, a -21% change from $596 million in the prior year.
• Gross Margin: The gross margin was $1,923 million, up 4% from $1,852 million in the prior year, representing 34.0% of net sales, a decrease of 0.1 percentage points.
• Operating Income: Operating income was $283 million, a 14% increase from $249 million in the prior year, representing 5.0% of net sales, an increase of 0.4 percentage points.
• Adjusted Operating Income: Adjusted operating income was $718 million, a -12% change from $815 million in the prior year.
• Free Cash Flow: Free cash flow was $257 million for the first half of the year, compared to - $144 million in the prior year.
• Cash Flows from Operations: Cash flows from operations were $510 million, up from $118 million in the prior year.

Segment Revenue (First Half 2026)

• Medical Products & Therapies: Total sales were $3,996 million, increasing 5% on a reported basis and 2% on an organic basis.
  • Infusion Therapies & Platforms: $3,361 million, up 4% (reported) and 1% (organic).
  • Advanced Surgery: $635 million, up 13% (reported) and 11% (organic).
• Healthcare Systems & Technologies: Total sales were $1,506 million, increasing 2% on a reported basis and 1% on an organic basis.
  • Care & Connectivity Solutions: $937 million, up 4% (reported) and 3% (organic).
  • Front Line Care: $569 million, a -0% reported change and -1% organic change.
• Other: Sales were $159 million, a -1% reported change and 0% organic change.

Outlook / Guidance

Baxter International Inc. raised its full-year 2026 financial outlook, now expecting reported sales growth from continuing operations to be between 3% and 4%. Organic sales growth from continuing operations is projected to be between 2% and 3%. Adjusted earnings from continuing operations per diluted share are forecast to range from $1.95 to $2.15.